SCHEMBL5755212

SCHEMBL5755212

C[C@@H](NS(=O)(=O)c1ccc2nc(SCC3CCCCC3)sc2c1)C(=O)NO

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
TSHR P16473 3/20 0.51
LMNA P02545 2/20 0.51
HTT P42858 2/20 0.51
HPGD P15428 2/20 0.51
HSP90AA1 P07900 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.44
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 1/20 0.43
CLK1 P49759 1/20 0.42
HSD17B10 Q99714 1/20 0.41
GAA P10253 1/20 0.41
MAOB P27338 1/20 0.41
ALOX15 P16050 1/20 0.40
THRB P10828 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756642 0.92 SMN1; SMN2 (0.50) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5757798 0.92 LMNA (0.52) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5755993 0.87 MMP2 (0.48) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5755594 0.87 ALDH1A1 (0.48) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5757831 0.86 SMN1; SMN2 (0.51) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5753490 0.83 LMNA (0.41) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5755972 0.83 POLB (0.48) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL6975596 0.82 SMN1; SMN2 (0.47) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5756059 0.82 RXFP1 (0.50) ALDH1A1TSHRLMNAHTTHPGD
SCHEMBL5755826 0.82 ALDH1A1 (0.49) ALDH1A1TSHRLMNAHTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 ALDH1A1 311/4885TSHR 4446/4885LMNA 1839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.